Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_.[A229338,A230348] It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration.[A230348] In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.[A230348] Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females.[A230378] Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria.[A230348] As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.[A230353,A230358]
Synonyms
Phosphomycin
cis-(1R,2S)-epoxypropylphosphonic acid
FCM
Phosphonemycin
Fosfocina
Fosfomycin tromethamine
Fosfomycinum
(2R-cis)-(3-Methyloxiranyl)phosphonic acid
Fosfomycin sodium
Phosphonomycin
(1R,2S)-epoxypropylphosphonic acid
Fosfomycine
Fosfomicina
1R-cis-(1,2-epoxypropyl)phosphonic acid
L-cis-1,2-epoxypropylphosphonic acid
Fosfomycin
Fosfomycin calcium monohydrate
(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid
Brand Names
Ivozfo
Contepo
Jamp-fosfomycin
Fosfomycin Tromethamine
Monurol
Fosfomycin tromethamine
Fosfomycin Powder for Oral Solution
Indication
Fosfomycin is indicated for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of _Escherichia coli_ and _Enterococcus faecalis_.[L31818] It is also indicated to treat adults with complicated urinary tract infections (cUTI), including acute pyelonephritis, caused by susceptible isolates of _Escherichia coli_ and _Klebsiella pneumoniae_.[L54511]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682